GlassScriptPhysician profile
Antonio Montgomery
NPI 1821115767
$3,639.20
in general payments reported to CMS, 2019-2025
26 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $366 · 2021: $550 · 2022: $328 · 2023: $726 · 2024: $367 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.65 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $920.62 | 2019-2024 | Xtandi |
| Coloplast Corp | $455.08 | 2019-2020 | |
| Davol INC. | $391.74 | 2021 | |
| Angiodynamics, INC. | $370.91 | 2023-2024 | Nanoknife |
| Urogen Pharma, INC. | $259.64 | 2025 | |
| Novo Nordisk INC | $144.15 | 2025 | Rivfloza |
| Janssen Biotech, INC. | $137.99 | 2019-2022 | |
| Pfizer INC. | $118.54 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.40 | 2022 | |
| Boston Scientific Corporation | $85.01 | 2025 | Lithovue |
| Ethicon US, LLC | $77.16 | 2022-2024 | Ethicon, Harmonic |
| Aspira Women'S Health INC | $70.47 | 2023 | Ova1 |
| Astellas Pharma Global Development | $63.82 | 2025 | Xtandi |
| Intuitive Surgical, INC. | $61.21 | 2023-2025 | Da Vinci Surgical System |
| Bayer Healthcare Pharmaceuticals INC. | $60.29 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $51.91 | 2023 | Prolaris |
| Novartis Pharmaceuticals Corporation | $43.55 | 2025 | |
| Myovant Sciences INC. | $38.48 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $31.64 | 2025 | Exparel |
| Dendreon Pharmaceuticals LLC | $29.72 | 2021 | |
| Ambu INC. | $28.58 | 2021 | |
| Merck Sharp & Dohme LLC | $24.57 | 2020 | |
| 180 Medical, INC. | $21.15 | 2019 | |
| Sumitomo Pharma America, INC. | $20.12 | 2025 | Orgovyx |
| Telix Pharmaceuticals | $17.25 | 2025 | Illuccix |
| Neotract INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.